Print（PDF/186KB） Apr. 08, 2026 Finances
Notice Regarding Refinancing of Existing Borrowings through a Bridge Loan
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Toru Kimura; Securities Code: 4506, Prime Market of TSE; the “Company”) announced today that the Company has decided to refinance its existing borrowings (hereinafter referred to as the “Refinancing”) through a bridge loan (hereinafter referred to as the “Bridge Loan”), as outlined below.
1. Purpose of the Refinancing
As announced in the “Notice Regarding Refinancing of Existing Borrowings Through a Syndicated Loan” dated March 26, 2025, the Company has entered into a syndicated loan agreement for the purpose of refinancing the bridge loan for the acquisition of Myovant Sciences Ltd. as a wholly owned subsidiary and existing borrowings for the strategic alliance with Roivant Sciences Ltd. implemented in December 2019.
In connection with the issuance of new shares and the secondary offering of its shares, as announced on April 8, 2026, the Company has decided to fully repay the existing borrowings guaranteed by Sumitomo Chemical Co., Ltd. and to refinance them through the Bridge Loan without a guarantee from Sumitomo Chemical Co., Ltd.
2. Overview of the Bridge Loan
Please scroll horizontally to view more information.
| Term Loan | Commitment Line | |
|---|---|---|
| Contract Amount | Total: 20.0 billion JPY | Total: 130.0 billion JPY |
| Use of Funds | Refinancing of existing borrowings | Working capital |
| Loan/Commitment Period | April 24, 2026 – April 23, 2027 | |
| Repayment Method | Lump sum repayment on due date | |
| Presence of Collateral | None | |
| Joint Guarantor | None | |
| Lenders | Sumitomo Mitsui Banking Corporation and others | |
3. Overview of the Existing Syndicated Loan to Be Repaid
Please scroll horizontally to view more information.
| Term Loan (Tranche A) |
Commitment Line (Tranche B) |
|
|---|---|---|
| Initial Facility Amount | 140.0 billion JPY | 93.0 billion JPY |
|
Outstanding Principal Balance (as of April 8, 2026) |
60.0 billion JPY | 38.1 billion JPY |
| Use of Funds | Refinancing of existing borrowings | Working capital |
| Loan/Commitment Period | March 31, 2025 – March 31, 2028 | |
| Repayment Method | Lump sum repayment on due date | |
| Presence of Collateral | None | |
| Joint Guarantor | Sumitomo Chemical Co., Ltd. | |
| Arranger & Agent | Sumitomo Mitsui Banking Corporation | |
| Co-Arranger | Sumitomo Mitsui Trust Bank, Limited | |
| Participating Financial Institutions |
Sumitomo Mitsui Banking Corporation Sumitomo Mitsui Trust Bank, Limited The Norinchukin Bank Mizuho Bank, Ltd. MUFG Bank, Ltd. The Hyakujushi Bank, Ltd. Aozora Bank, Ltd. The Iyo Bank, Ltd. San ju San Bank, Ltd. The Shiga Bank, Ltd. The Joyo Bank, Ltd. The Hiroshima Bank, Ltd. The Oita Bank, Ltd. The Chiba Bank, Ltd. The Nanto Bank, Ltd. The Kiyo Bank, Ltd. |
|
4. Future Outlook
The impact of the Refinancing on the Company’s consolidated financial results for the fiscal year ending March 2027 is expected to be minimal.
- Disclaimer Regarding Forward-looking Statements
- The statements made in this press release contain forward-looking statements based on management's assumptions and beliefs in light of information available as of the day of this release, which involve both known and unknown risks and uncertainties. Actual results of those matters covered in the forward-looking statements including financial forecast may differ materially from those contained in this release, due to a number of factors.
Inquiries from the Press